<DOC>
	<DOCNO>NCT01639326</DOCNO>
	<brief_summary>This study aim use correspond pharmacogenetic analysis increase dose irinotecan scheme commonly use standard chemotherapy advance colorectal cancer treatment first . The project aim improve therapeutic index chemotherapy . This optimization raise base administration different dos drug depend genotype UGT1A1 gene . The research team propose project demonstrate administration high dos irinotecan FOLFIRI scheme patient genotype UGT1A1 favorable ( wild homozygous * 1 / * 1 heterozygous * 1 / * 28 ) , significantly improve efficiency antineoplastic agent without significant increase toxicity . Secondarily ass possible prognostic factor related tolerance efficacy . The primary objective evaluate efficacy high dos irinotecan FOLFIRI scheme patient metastatic colorectal cancer favorable genotype UGT1A1 ( wild homozygous * 1 / * 1 heterozygous * 1 / * 28 ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety FOLFIRI-AD Patients With Metastatic Colorectal Cancer UGT1A Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologically confirm metastatic colorectal adenocarcinoma curable surgically . Not receive prior systemic therapy metastatic colorectal cancer . It allow receive neoadjuvant adjuvant chemotherapy ( without irinotecan ) treatment primary tumor least six month inclusion . All toxicity secondary previous treatment resolve inclusion . The progression disease ( metastatic disease ) confirm radiologically adjuvant treatment . Genotype gene UGT1A1 * 1 / * 1 * 1 / * 28 Age &gt; = 18 &lt; 75 year . ECOG 01 . Measurable disease accord RECIST version 1.1 Life expectancy &gt; equal 3 month . Informed consent , date sign . Adequate bone marrow function : Hemoglobin ≥ 9.0 g / dl ( patient hemoglobin &lt; 9 g / dl may transfuse inclusion study ) Platelet count ≥ 100 x 109 / L Absolute neutrophil count ( ANC ) ≥ 1.5x 109 / L Adequate liver function : Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN absence liver metastases ALT AST ≤ 5 × ULN presence liver metastases Alkaline phosphatase ≤ 2.5 x ULN ≤ 5 x ULN presence liver metastases ≤ 10 x ULN presence bone metastases Adequate renal function creatinine level &lt; 1.5 mg / dL . BUN &gt; 50 ml / min Genotype gene UGT1A1 * 28 / * 28 ( Gilbert 's syndrome ) Patients pregnant breastfeed Concomitant treatment antineoplastic therapy specify . Patients active infectious process patient immunosuppressive therapy , chronic anticoagulant therapy . History malignancy last five year except basal cell carcinoma skin carcinoma situ cervix treat properly . Patients positive serology HIV previously know , chronic diarrhea , inflammatory bowel disease malabsorption syndrome tumor obstruction unresolved . Clinically significant cardiovascular disease : cerebrovascular accident / stroke ( ≤ 6 month inclusion trial ) , myocardial infarction ( ≤ 6 month inclusion trial ) , unstable angina , uncontrolled hypertension , congestive heart failure grade II high NYHA serious cardiac arrhythmia . Patients significant neurological psychiatric disorder , include dementia poorly control epilepsy . Patients contraindication specify Summary study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>